Operator: Good day and thank you for standing by. Welcome to the Nektar Therapeutics' Third Quarter 2024 Financial Results Conference Call.
Keep Reading →
November 9 - News, Transcripts
Operator: Good day, and thank you for standing by. Welcome to the Nektar Therapeutics First Quarter 2024 Financial Results Conference Call. [Operator Instructions].
Keep Reading →
May 10 - News, Transcripts
Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.22 EPS, expectations were $-0.2.
Keep Reading →
March 5 - News, Transcripts
Operator: Good day and thank you for standing by. Welcome to the Nektar Therapeutics Third Quarter 2023 Financial Results Conference Call.
Keep Reading →
November 9 - News, Transcripts
Investors are optimistic as we move into the third quarter earnings season.
Keep Reading →
October 23 - Hedge Funds, News
Operator: Good day and thank you for standing by. Welcome to the Nektar Therapeutics Second Quarter 2023 Financial Results Conference Call.
Keep Reading →
August 10 - News, Transcripts
Operator: Good day and thank you for standing by. Welcome to the Nektar Therapeutics First Quarter 2023 Financial Results Conference Call.
Keep Reading →
May 10 - News, Transcripts
In this article, we present the 10 pharmaceutical stocks that are being downgraded by analysts.
Keep Reading →
April 20 - Hedge Funds, News
In this article, we look at why billionaire Stanley Druckenmiller just dumped 10 stocks from his portfolio.
Keep Reading →
March 1 - Hedge Funds, News
In this piece, we will take a look at the 5 healthcare stocks to buy according to Lee Ainslie's Maverick Capital. If you want to learn more about Mr.
Keep Reading →
December 22 - Hedge Funds, News
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns.
Keep Reading →
December 13 - Hedge Funds, News
The Insider Monkey team has completed processing the quarterly 13F filings for the June quarter submitted by the hedge funds and other money managers included in our extensive...
Keep Reading →
October 25 - Hedge Funds, News
In this article, we will discuss 5 pharmaceutical stocks to buy today according to Tiger Cub Billionaire Lee Ainslie.
Keep Reading →
September 20 - Hedge Funds, News
Is Nektar Therapeutics (NASDAQ:NKTR) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment...
Keep Reading →
July 26 - Hedge Funds, News
We at Insider Monkey have gone over 817 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio...
Keep Reading →
December 18 - Hedge Funds, News
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming).
Keep Reading →
September 28 - Hedge Funds, News
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming).
Keep Reading →
August 12 - Hedge Funds, News
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the...
Keep Reading →
June 23 - Hedge Funds, News
We hate to say this but, we told you so.
Keep Reading →
March 29 - Hedge Funds, News
We can judge whether Nektar Therapeutics (NASDAQ:NKTR) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas...
Keep Reading →
December 10 - Hedge Funds, News
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through October 17th.
Keep Reading →
October 28 - Hedge Funds, News
James Dondero doesn’t back down. That’s what helped him build Highland Capital Management into a credit giant that at one point oversaw $40 billion.
Keep Reading →
October 18 - Hedge Funds, Insider Trading
An ongoing legal battle between the high-powered hedge fund D.E.
Keep Reading →
September 10 - Hedge Funds, Insider Trading
Hedge funds are not perfect. They have their bad picks just like everyone else.
Keep Reading →
June 23 - Hedge Funds, News
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing.
Keep Reading →
April 22 - Hedge Funds, News
We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio...
Keep Reading →
December 13 - Hedge Funds, News
The biotech industry is regaining ground it lost in 2016 at full speed.
Keep Reading →
July 19 - Hedge Funds, News
Shares in Rovio Entertainment Ltd.
Keep Reading →
March 2 - Market Movers, News
Tetraphase Pharmaceuticals Inc's Ignite3 trial evaluating the company's lead drug candidate eravacycline for treating complicated urinary tract infections, or cUTIs, failed to...
Keep Reading →
February 14 - Market Movers, News
Nektar Therapeutics (NASDAQ:NKTR) is one of the week’s biggest winners in biotech so far, with the company soaring during the Monday session on the release of a fresh round ...
Keep Reading →
March 21 - News, Stock Analysis
Although the broader markets are relatively calm, five stocks, Nektar Therapeutics (NASDAQ:NKTR), Advanced Micro Devices, Inc.
Keep Reading →
March 20 - News
The worries about the election and the ongoing uncertainty about the path of interest-rate increases have been keeping investors on the sidelines.
Keep Reading →
December 13 - Hedge Funds, News
Bihua Chen's Cormorant Asset Management is one of some 750 investors that we track and whose quarterly 13F filings we analyze to identify stocks that they are collectively bullish...
Keep Reading →
November 7 - Hedge Funds, News
According to research firm TrimTabs, the dollar volume of insider buying from early-October through the end of last week stood at about $110 million, representing the lowest monthly...
Keep Reading →
October 26 - Insider Trading, News
It’s been another busy start to the week in biotech, with a number of companies moving double digit percentage points on various fundamental releases.
Keep Reading →
October 20 - Market Movers, News
Stocks indexes have jumped higher today amid better-than-expected earnings from Netflix, Inc. (NASDAQ:NFLX) and Goldman Sachs Group Inc (NYSE:GS), and a rally in oil prices.
Keep Reading →
October 18 - Market Movers, News
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy...
Keep Reading →
November 25 - Hedge Funds, News
Cheyne Capital is one of the few non-U.S firms that we track in our database.
Keep Reading →
October 21 - Hedge Fund Analysis, Hedge Funds, News
Stan Druckenmiller’s Duquesne Family Office LLC, previously Duquesne Capital, has filed its 13F for the reporting period of March 31.
Keep Reading →
May 28 - Hedge Funds, News
This is close to the market cap that Bank of America's Steve Byrne thinks MannKind Corporation (NASDAQ:MNKD) is worth.
Keep Reading →
September 17 - News
Now, according to many of your peers, hedge funds are assumed to be useless, outdated investment vehicles of a forgotten age.
Keep Reading →
September 17 - News
To many investors, hedge funds are assumed to be bloated, outdated investment tools of a forgotten age.
Keep Reading →
September 11 - News
If you were to ask many of your fellow readers, hedge funds are seen as overrated, old investment vehicles of a period lost to current times.
Keep Reading →
August 30 - News
Nektar Therapeutics (NASDAQ:NKTR) announced data last week that could become a breakthrough in the largest healthcare market in the U.S.
Keep Reading →
June 26 - News
While the market jittered this week over what the Federal Reserve will do next, some stocks didn't flinch.
Keep Reading →
June 24 - News
Nektar Therapeutics (NASDAQ:NKTR) was in 8 hedge funds' portfolio at the end of March.
Keep Reading →
June 12 - News
Sarepta Therapeutics Inc (NASDAQ:SRPT) was in 19 hedge funds' portfolio at the end of March.
Keep Reading →
June 3 - News
Earnings season is getting ready to rev into high gear, but earnings are unlikely to be the talk of the sector in the days to come, with three big Food and Drug Administration...
Keep Reading →
April 14 - News
Acorda Therapeutics Inc (NASDAQ:ACOR) was in 10 hedge funds' portfolio at the end of the fourth quarter of 2012.
Keep Reading →
April 12 - News
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated.
Keep Reading →
April 10 - News